Moleculin Biotech, Inc. (MBRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+983.9%

$90.18

vs $8.32 price

Levered DCF

$143.83

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-19.26

Distress zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.12×	-0.22×	-0.85×	-1.04×	-3.15×	-2.71×	-2.82×	-2.27×
P/B	0.26×	0.98×	0.98×	0.58×	0.63×	2.63×	2.39×	1.89×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.14×	-0.09×	-0.08×	0.43×	1.32×	-1.65×	-2.03×	-1.33×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	1.41×	0.97×	3.86×	9.46×	20.02×	5.89×	3.78×	2.06×
Debt / equity	0.02×	0.08×	0.02×	0.01×	0×	0.02×	0.02×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-223.6%	-364.0%	-114.2%	-55.6%	-20.1%	-97.0%	-84.8%	-83.2%
Return on invested capital	-162.9%	-228.0%	-94.1%	-58.1%	-28.5%	-74.9%	-79.1%	-95.7%
Return on assets	-151.7%	-128.6%	-77.9%	-50.5%	-18.9%	-59.5%	-52.3%	-60.6%
Free cash flow yield	-579.8%	-407.9%	-95.2%	-91.4%	-38.0%	-38.5%	-46.3%	-46.8%
Earnings yield	-855.9%	-371.8%	-117.0%	-95.7%	-31.8%	-36.8%	-35.4%	-44.1%
Enterprise value	-$4.6M	$2.1M	$2.5M	-$12.4M	-$20.8M	$32.2M	$26.9M	$19.8M
Net debt / EBITDA	0.25×	0.18×	0.78×	1.48×	4.5×	0.76×	0.78×	0.48×
Cash conversion cycle (days)	-14,227	0	0	0	0	0	-4,248	-6,688